Effect of the p38MAPKinhibitor doramapimod on the systemic inflammatory response to intravenous lipopolysaccharide in horses
AuthorBauquier, J; Tudor, E; Bailey, S
Source TitleJournal of Veterinary Internal Medicine
Veterinary Clinical Sciences
Document TypeJournal Article
CitationsBauquier, J., Tudor, E. & Bailey, S. (2020). Effect of the p38MAPKinhibitor doramapimod on the systemic inflammatory response to intravenous lipopolysaccharide in horses. JOURNAL OF VETERINARY INTERNAL MEDICINE, 34 (5), pp.2109-2116. https://doi.org/10.1111/jvim.15847.
Access StatusOpen Access
BACKGROUND: Doramapimod, a p38 MAPK inhibitor, is a potent anti-inflammatory drug that decreases inflammatory cytokine production in equine whole blood in vitro. It may have benefits for treating systemic inflammation in horses. OBJECTIVE: To determine whether doramapimod is well tolerated when administered IV to horses, and whether it has anti-inflammatory effects in horses in a low-dose endotoxemia model. ANIMALS: Six Standardbred horses. METHODS: Tolerability study, followed by a blinded, randomized, placebo-controlled cross-over study. Horses were given doramapimod, and clinical and clinicopathological variables were monitored for 24 hours. Horses then were treated with doramapimod or placebo, followed by a low dose infusion of lipopolysaccharide (LPS). Clinical variables (heart rate, rectal temperature, noninvasive blood pressure), leukocyte count and tumor necrosis factor alpha (TNF-α) and interleukin-1 beta (IL-1β) concentrations were measured at multiple time points until 6 hours post-LPS infusion. RESULTS: No adverse effects or clinicopathological changes were seen in the safety study. When treated with doramapimod as compared to placebo, horses had significantly lower heart rates (P = .03), rectal temperatures (P = .03), and cytokine concentrations (P = .03 for TNF-α and IL-1β), and a significantly higher white blood cell count (P = .03) after LPS infusion. CONCLUSIONS AND CLINICAL IMPORTANCE: Doramapimod has clinically relevant anti-inflammatory effects in horses, likely mediated by a decrease in leukocyte activation and decrease in the release of pro-inflammatory cytokines. To evaluate its potential as a novel treatment for systemic inflammatory response syndrome in horses, clinical trials will be necessary to determine its efficacy in naturally occurring disease.
- Click on "Export Reference in RIS Format" and choose "open with... Endnote".
- Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References